This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Our Medicine

NovoSeven® is indicated for the treatment of bleeding  episodes and for the prevention of bleeding in surgery or  invasive procedures in patients with congenital haemophilia  with inhibitors to coagulation factors VIII or IX, congenital  haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII  deficiency, and Glanzmann’s thrombasthenia with past or  present refractoriness to platelet transfusions or where  platelets are not readily available.1

NovoSeven® is indicated for the treatment of severe  postpartum haemorrhage when uterotonics are insufficient  to achieve haemostasis.1,3

Explore NovoThirteen® 6

1. NovoSeven® Summary of Product Characteristics. SFDA Label.

2. Maahs J et al. J Blood Med. 2014;5:153–156.

3. Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.

4. Chowdary P et al. Res Pract Thromb Haemost 2019; 3:542-554.

5.Esperoct® Summary of Product Characteristics


6. NovoThirteen® Summary of Product Characteristics.